By Sabela Ojea

Boston Scientific said the U.S. Food and Drug Administration has granted approval to its Watchman Flx Pro Left Atrial Appendage Closure device for use in nonvalvular atrial fibrillation patients.

The biotechnology engineering company said the device is designed for patients that are eligible for anticoagulation therapy.

Its technology is indicated to reduce stroke risk in patients with nonvalvular atrial fibrillation who need an alternative to oral anticoagulation therapy, the company added.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

September 06, 2023 16:32 ET (20:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Boston Scientific (NYSE:BSX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Boston Scientific 차트를 더 보려면 여기를 클릭.
Boston Scientific (NYSE:BSX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Boston Scientific 차트를 더 보려면 여기를 클릭.